Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AnaptysBio, Inc.
This study is a Phase 2 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged 18 years or older
A diagnosis of Rheumatoid Arthritis based on ACR/EULAR 2010 classification criteria, for at least 3 months before participating in the trial
Must be receiving treatment with at least 1, but not more than 2 csDMARDs for at least 3 months and be on stable dosages for at least 8 weeks prior to joining and throughout the trial
Have had an inadequate response to, or loss of response or intolerance to at least 1 conventional synthetic DMARD (csDMARD), biologic DMARD (bDMARD), or targeted synthetic DMARD (tsDMARD) treatment
You may not be if
History of an inflammatory joint disease other than Rheumatoid Arthritis
Prior exposure to a PD-1 or PD-L1 agonist, antagonist, or modulator
History of cancer within the last 5 years (except for some skin cancers)
Any known or suspected condition that would compromise immune status
Pregnant or breastfeeding women
Clareo Health | A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
